Bevacizumab in the Treatment of Refractory Brain Edema in High-grade Glioma

Aysha K Alsahlawi; Claudie Michaud-Couture; Alexandre Lachance; Samuel Bergeron-Gravel; Mélanie Létourneau; Catherine Bourget; Peter V Gould; Panagiota Giannakouros; Emily M Nakada; Damien Faury; Louis Crevier; Éric Bouffet; Nada Jabado; Valérie Larouche; Samuele Renzi

doi:10.1097/MPH.0000000000002792

Bevacizumab in the Treatment of Refractory Brain Edema in High-grade Glioma

J Pediatr Hematol Oncol. 2024 Jan 1;46(1):e87-e90. doi: 10.1097/MPH.0000000000002792. Epub 2023 Nov 30.

Authors

Aysha K Alsahlawi¹, Claudie Michaud-Couture², Alexandre Lachance², Samuel Bergeron-Gravel³, Mélanie Létourneau³, Catherine Bourget⁴, Peter V Gould⁵, Panagiota Giannakouros⁶, Emily M Nakada⁷, Damien Faury⁷, Louis Crevier⁸, Éric Bouffet^{9

10}, Nada Jabado⁷, Valérie Larouche⁶, Samuele Renzi⁶

Affiliations

¹ Department of Neurological Surgery, McGill University, Montreal, Canada.
² Faculty of Medicine, Université Laval, Quebec, Canada.
³ Division of Radiation Oncology, CHU de Québec - Université Laval, Quebec, Canada.
⁴ Department of Diagnostic Radiology, CHU de Québec - Université Laval, Quebec, Canada.
⁵ Division of Molecular Biology, Medical Biochemistry and Pathology, CHU de Québec - Université Laval, Quebec, Canada.
⁶ Department of Pediatrics, Division of Hemato-Oncology, CHU de Québec-Université Laval, Quebec, Canada.
⁷ Department of Pediatrics, McGill University, and The Research Institute of the McGill University Health Centre, Montreal, Canada.
⁸ Division of Neurosurgery, Department of Surgery, CHU de Québec - Université Laval, Quebec, Canada.
⁹ The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
¹⁰ Division of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.

PMID: 38032194
DOI: 10.1097/MPH.0000000000002792

Abstract

We report the case of a 14-year-old boy with a steroid-dependent refractory tumor whose longstanding dexamethasone treatment was successfully discontinued after a course of bevacizumab. The use of bevacizumab despite the absence of clear evidence of radionecrosis allowed a significant decrease in the amount of the brain edema.

Publication types

Case Reports

MeSH terms

Adolescent
Angiogenesis Inhibitors / therapeutic use
Bevacizumab / therapeutic use
Brain Edema* / drug therapy
Brain Edema* / etiology
Brain Neoplasms* / complications
Brain Neoplasms* / drug therapy
Brain Neoplasms* / pathology
Glioma* / complications
Glioma* / drug therapy
Glioma* / pathology
Humans
Male
Radiation Injuries*

Substances

Bevacizumab
Angiogenesis Inhibitors